scholarly journals STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review

2019 ◽  
Vol 38 (1) ◽  
Author(s):  
Jiang-Jiang Qin ◽  
Li Yan ◽  
Jia Zhang ◽  
Wei-Dong Zhang
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Triple Negative Breast Cancer ◽  
Therapeutic Target ◽  
Triple Negative ◽  
Potential Therapeutic Target

c-Met as a potential therapeutic target in triple negative breast cancer

2020 ◽  
pp. 295-326
Author(s):  
Sapana Sameer Chaudhary ◽  
Sameer Choudhary ◽  
Sakshi Rawat ◽  
Gouri Ahir ◽  
Anwar L. Bilgrami ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Therapeutic Target ◽  
Triple Negative ◽  
Potential Therapeutic Target

Abstract 4373: LRP5: a potential therapeutic target in triple-negative breast cancer.

2013 ◽  
Author(s):  
Sylvie Maubant ◽  
Virginie Maire ◽  
Bruno Tesson ◽  
David Gentien ◽  
Bérengère Marty-Prouvost ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Therapeutic Target ◽  
Triple Negative ◽  
Potential Therapeutic Target

scholarly journals ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer

2020 ◽  
Vol 21 (3) ◽  
pp. 903 ◽  
Author(s):  
Saioa Mendaza ◽  
Ane Ulazia-Garmendia ◽  
Iñaki Monreal-Santesteban ◽  
Alicia Córdoba ◽  
Yerani Ruiz de Azúa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Methylation ◽  
Cell Proliferation ◽  
Triple Negative Breast Cancer ◽  
Therapeutic Target ◽  
Triple Negative ◽  
Potential Therapeutic Target ◽  
Epidermal Growth Factor Domain ◽  
Tnbc Cell ◽  
Factor C

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and currently lacks any effective targeted therapy. Since epigenetic alterations are a common event in TNBC, DNA methylation profiling can be useful for identifying potential biomarkers and therapeutic targets. Here, genome-wide DNA methylation from eight TNBC and six non-neoplastic tissues was analysed using Illumina Human Methylation 450K BeadChip. Results were validated by pyrosequencing in an independent cohort of 50 TNBC and 24 non-neoplastic samples, where protein expression was also assessed by immunohistochemistry. The functional role of disintegrin and metalloproteinase domain-containing protein 12(ADAM12) in TNBC cell proliferation, migration and drug response was analysed by gene expression silencing with short hairpin RNA. Three genes (Von Willenbrand factor C and Epidermal Growth Factor domain-containing protein (VWCE), tetraspanin-9 (TSPAN9) and ADAM12) were found to be exclusively hypomethylated in TNBC. Furthermore, ADAM12 hypomethylation was associated with a worse outcome in TNBC tissues and was also found in adjacent-to-tumour tissue and, preliminarily, in plasma from TNBC patients. In addition, ADAM12 silencing decreased TNBC cell proliferation and migration and improved doxorubicin sensitivity in TNBC cells. Our results indicate that ADAM12 is a potential therapeutic target and its hypomethylation could be a poor outcome biomarker in TNBC.

524 LRP5: a Potential Therapeutic Target in Triple-negative Breast Cancer

2012 ◽  
Vol 48 ◽  
pp. 161-162
Author(s):  
S. Maubant ◽  
V. Maire ◽  
B. Tesson ◽  
D. Gentien ◽  
B. Marty-Prouvost ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Therapeutic Target ◽  
Triple Negative ◽  
Potential Therapeutic Target

scholarly journals Lung-Derived Selectins Enhance Metastatic Behavior of Triple Negative Breast Cancer Cells

Biomedicines ◽  
2021 ◽  
Vol 9 (11) ◽  
pp. 1580
Author(s):  
Sami U. Khan ◽  
Ying Xia ◽  
David Goodale ◽  
Gabriella Schoettle ◽  
Alison L. Allan
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Therapeutic Target ◽  
Triple Negative ◽  
Ex Vivo ◽  
Metastatic Progression ◽  
Wild Type ◽  
Potential Therapeutic Target ◽  
Metastatic Behavior

The lung is one of the deadliest sites of breast cancer metastasis, particularly for triple negative breast cancer (TNBC). We have previously shown that the lung produces several soluble factors that may enhance the metastatic behavior of TNBC, including E-, L-, and P-selectin. In this paper, we hypothesize that lung-derived selectins promote TNBC metastatic behavior and may serve as a potential therapeutic target. Lungs were isolated from mice and used to generate lung-conditioned media (CM). Lung-derived selectins were immunodepleted and TNBC migration and proliferation were assessed in response to native or selectin-depleted lung-CM. A 3D ex vivo pulmonary metastasis assay (PuMA) was used to assess the metastatic progression of TNBC in the lungs of wild-type versus triple-selectin (ELP-/-) knockout mice. We observed that individual lung-derived selectins enhance in vitro migration (p ≤ 0.05), but not the proliferation of TNBC cells, and that ex vivo metastatic progression is reduced in the lungs of ELP-/- mice compared to wild-type mice (p ≤ 0.05). Treatment with the pan-selectin inhibitor bimosiamose reduced in vitro lung-specific TNBC migration and proliferation (p ≤ 0.05). Taken together, these results suggest that lung-derived selectins may present a potential therapeutic target against TNBC metastasis. Future studies are aimed at elucidating the pro-metastatic mechanisms of lung-derived selectins and developing a lung-directed therapeutic approach.

Sign in / Sign up

Export Citation Format

Share Document